Business
Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences
Guggenheim Genomic Medicines and Rare Disease Conference on April 1, 2022 at 4:00 pm ET 21st Annual Needham Virtual Healthcare Conference April 11, 2022 at
About this update from Taysha Gene Therapies, Inc.
[{"type":"text","content":"\nGuggenheim Genomic Medicines and Rare Disease Conference on April 1, 2022 at 4:00 pm ET\n\n21st Annual Needham Virtual Healthcare Conference April 11, 2022 at 11:45 am ET\n\n DALLAS--(BUSINESS WIRE)--\nTaysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in upcoming fireside chats at the Guggenheim Genomic Medicines and Rare Disease Day Conference and the 21st Annual Needham Virtual Healthcare Conference.\n\n\n\nConference Details:\n\n\n\n\n \n\n\n\n\n\nEvent:\n\n\n\n\nGuggenheim Genomic Medicines and Rare Disease Day Conference\n\n\n\n\n\nDate:\n\n\n\n\nApril 1, 2022\n\n\n\n\n\nTime:\n\n\n\n\n4:00 pm ET\n\n\n\n\n\nFormat:\n\n\n\n\nFireside Chat\n\n\n\n\n\nParticipants:\n\n\n\n\nRA Session II, President, Founder and CEO\n\n\n\n\n\n \n\n\n\n\nDr. Suyash Prasad, Chief Medical Officer and Head of R&D\n\n\n\n\n\n \n\n\n\n\nKamran Alam, Chief Financial Officer\n\n\n\n\n\n \n\n\n\n\n \n\n\n\n\n\nConference Details:\n\n\n\n\n \n\n\n\n\n\nEvent:\n\n\n\n\n21st Annual Needham Virtual Healthcare Conference\n\n\n\n\n\nDate:\n\n\n\n\nApril 11, 2022\n\n\n\n\n\nTime:\n\n\n\n\n11:45 am ET\n\n\n\n\n\nFormat:\n\n\n\n\nFireside Chat\n\n\n\n\n\nParticipants:\n\n\n\n\nRA Session II, President, Founder and CEO\n\n\n\n\n\n \n\n\n\n\nDr. Suyash Prasad, Chief Medical Officer and Head of R&D\n\n\n\n\n\n \n\n\n\n\nKamran Alam, Chief Financial Officer\n\n\n\n\nAbout Taysha Gene Therapies\n\nTaysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.\nView source version on businesswire.com: https://www...